In situ detection of early stages and late stages HPV infection

  • US 8,859,218 B2
  • Filed: 06/10/2009
  • Issued: 10/14/2014
  • Est. Priority Date: 06/13/2008
  • Status: Active Grant
First Claim
Patent Images

1. A method of detecting papillomavirus infection in a human subject and determining a risk of the human subject developing a cancerous lesion, comprising:

  • receiving a sample obtained from the human subject, the sample comprising a population of cells susceptible to infection by a papillomavirus,applying the sample to a slide;

    contacting the sample with a first staining reagent comprising an anti-HPV monoclonal antibody generated against a purified recombinant papillomavirus protein, whereinthe monoclonal antibody specifically binds to two or more native HPV proteins from different HPV types, whereinthe two or more native HPV proteins are native E7 proteins from different HPV types or native E6 proteins from different HPV types, andthe monoclonal antibody is capable of binding in situ to said proteins in a clinical sample; and

    a positive staining is indicative of the presence of a papillomavirus protein in the sample thereby indicating papillomavirus infection in the human subject; and

    determining a nuclear to cytoplasm ratio in size for at least one cell of the population of cells; and

    determining a score for the sample based on the nuclear to cytoplasm ratio in size and the positive staining wherein the score indicates a risk of the human subject developing a cancerous lesion.

View all claims
    ×
    ×

    Thank you for your feedback

    ×
    ×